MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581695 | Name: Phenanthrene, decafluoro-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Phenanthrene, decafluoro- is a biochemical.

Chemical Structure

Phenanthrene, decafluoro-
Phenanthrene, decafluoro-
CAS#1580-20-7

Theoretical Analysis

MedKoo Cat#: 581695

Name: Phenanthrene, decafluoro-

CAS#: 1580-20-7

Chemical Formula: C14F10

Exact Mass: 357.9840

Molecular Weight: 358.14

Elemental Analysis: C, 46.95; F, 53.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Decafluorophenanthrene; Phenanthrene,decafluoro-(7CI,8CI,9CI); Perfluorophenanthrene; D2803; Perfluorphenanthren; Phenanthrene,1,2,3,4,5,6,7,8,9,10-decafluoro; Decafluorphenanthren; Phenanthrene, decafluoro-.
IUPAC/Chemical Name
1,2,3,4,5,6,7,8,9,10-Decafluorophenanthrene
InChi Key
BTRWUZQEZSPCPS-UHFFFAOYSA-N
InChi Code
InChI=1S/C14F10/c15-5-1-2-4(10(20)14(24)12(22)6(2)16)8(18)7(17)3(1)9(19)13(23)11(5)21
SMILES Code
FC1=C(F)C2=C(F)C(F)=C(F)C(F)=C2C3=C(F)C(F)=C(F)C(F)=C13
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 358.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fuentes MÁ, Muñoz BK, Jacob K, Vendier L, Caballero A, Etienne M, Pérez PJ. Functionalization of non-activated C-H bonds of alkanes: an effective and recyclable catalytic system based on fluorinated silver catalysts and solvents. Chemistry. 2013 Jan 21;19(4):1327-34. doi: 10.1002/chem.201203566. Epub 2012 Nov 29. PubMed PMID: 23197347. 2: Lai CZ, Fierke MA, Corrêa da Costa R, Gladysz JA, Stein A, Bühlmann P. Highly selective detection of silver in the low ppt range with ion-selective electrodes based on ionophore-doped fluorous membranes. Anal Chem. 2010 Sep 15;82(18):7634-40. doi: 10.1021/ac1013767. PubMed PMID: 20799720; PubMed Central PMCID: PMC2941663. 3: Feng X, Li Q, Gu J, Cotton FA, Xie Y, Schaefer HF 3rd. Perfluorinated polycyclic aromatic hydrocarbons: anthracene, phenanthrene, pyrene, tetracene, chrysene, and triphenylene. J Phys Chem A. 2009 Feb 5;113(5):887-94. doi: 10.1021/jp809110f. PubMed PMID: 19133794. 4: Celik L, Yücesoy M, Saatci AO, Kaynak S. Microbial growth in various perfluorocarbon liquids. Ophthalmic Surg Lasers Imaging. 2005 May-Jun;36(3):254-7. PubMed PMID: 15957486. 5: Baslar Z, Aras C, Unal M, Kayiran A, Ustundag S, Ozkan S. In vitro effect of silicone oil and liquid perfluorocarbons on platelet aggregation. Eur J Ophthalmol. 2004 Nov-Dec;14(6):550-4. PubMed PMID: 15638106. 6: Stolba U, Krepler K, Velikay-Parel M, Binder S. The effect of specific gravity of perfluorocarbon liquid on the retina after experimental vitreous substitution. Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):931-6. Epub 2004 Jul 17. PubMed PMID: 15258774. 7: Malchiodi-Albedi F, Morgillo A, Formisano G, Paradisi S, Perilli R, Scalzo GC, Scorcia G, Caiazza S. Biocompatibility assessment of silicone oil and perfluorocarbon liquids used in retinal reattachment surgery in rat retinal cultures. J Biomed Mater Res. 2002 Jun 15;60(4):548-55. PubMed PMID: 11948513. 8: Ghoraba HH, Zayed AI. Suprachoroidal hemorrhage as a complication of vitrectomy. Ophthalmic Surg Lasers. 2001 Jul-Aug;32(4):281-8. PubMed PMID: 11475392. 9: Cekiç O, Batman C, Totan Y, Aslan O, Ozalp S. Management of traumatic retinal detachment with vitreon in children. Int Ophthalmol. 1999;23(3):145-8. PubMed PMID: 11456251. 10: Gurelik G, Akata F, Bilgihan K, Hasanreisoğlu B. Effects of perfluorophenanthrene on the human corneal endothelium. Int Ophthalmol. 1998;22(6):377-83. PubMed PMID: 10937854. 11: Loewenstein A, Humayun MS, de Juan E Jr, Campochiaro PA, Haller JA. Perfluoroperhydrophenanthrene versus perfluoro-n-octane in vitreoretinal surgery. Ophthalmology. 2000 Jun;107(6):1078-82. PubMed PMID: 10857826. 12: Scott IU, Murray TG, Flynn HW Jr, Smiddy WE, Feuer WJ, Schiffman JC. Outcomes and complications associated with perfluoro-n-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair. Ophthalmology. 2000 May;107(5):860-5. PubMed PMID: 10811075. 13: Hegazy HM, Peyman GA, Liang C, Unal MH, Molinari LC, Kazi AA. Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR. Int Ophthalmol. 1998-1999;22(4):239-46. PubMed PMID: 10674869. 14: Batman C, Cekiç O, Totan Y, Aslan O, Ozalp S. Intraocular pressure changes in the vitreon study. Ophthalmic Surg Lasers. 1999 Nov-Dec;30(9):721-6. PubMed PMID: 10574493. 15: Meffert S, Peyman GA. Intraoperative complications of perfluoroperhydrophenanthrene: subretinal perfluorocarbon, retinal slippage and residual perfluorocarbon. Vitreon Study Group. Can J Ophthalmol. 1999 Aug;34(5):272-80. PubMed PMID: 10486686. 16: Wafapoor H, Kertes PJ, Navarro GC, Peyman GA, Meffert S, Ganiban GJ, Vierling S. The adjunctive use of perfluoroperhydrophenanthrene (Vitreon) in diabetic vitrectomy. Int Ophthalmol. 1998-1999;22(2):89-96. PubMed PMID: 10472768. 17: Liang C, Peyman GA. Tolerance of extended-term vitreous replacement with perfluoro-n-octane and perfluoroperhydrophenanthrene mixture (phenoctane). Retina. 1999;19(3):230-7. PubMed PMID: 10380029. 18: Stolba U, Krepler K, Velikay M, Binder S. Anterior segment changes in rabbits after experimental aqueous replacement with various amounts of different perfluorocarbon liquids. Graefes Arch Clin Exp Ophthalmol. 1999 Jun;237(6):501-7. PubMed PMID: 10379612. 19: Batman C, Cekic O. Effects of the long-term use of perfluoroperhydrophenanthrene on the retina. Ophthalmic Surg Lasers. 1998 Feb;29(2):144-6. PubMed PMID: 9507258. 20: Kertes PJ, Wafapoor H, Peyman GA, Calixto N Jr, Thompson H. The management of giant retinal tears using perfluoroperhydrophenanthrene. A multicenter case series. Vitreon Collaborative Study Group. Ophthalmology. 1997 Jul;104(7):1159-65. PubMed PMID: 9224470.